Phase II Study of Adding Ruxolitinib to Pembrolizumab Immunotherapy for Treating Relapsed or Refractory T-cell and 9p Amplified Lymphomas

What this Trial Is About

Researchers are studying whether adding the drug ruxolitinib to the immunotherapy pembrolizumab is safe and effective for treating relapsed or refractory types of T-cell lymphoma, including peripheral T-cell lymphoma PTCL, cutaneous T-cell lymphoma CTCL, and other lymphomas such as Hodgkin Lymphoma HL, Gray Zone Lymphoma GZL, and Primary Mediastinal B-cell Lymphoma PMBCL. The goal is to see how many patients achieve complete remission or show improvement with this combination treatment. This is a phase II clinical trial exploring new options for lymphomas that have returned or not responded to previous chemotherapy. Participants will receive ruxolitinib orally at a dose of 20 mg twice daily for up to 12 months, until the disease progresses, or side effects become intolerable. Pembrolizumab will be given intravenously at 200 mg every 21 days for up to 12 months or 17 treatment cycles. After finishing ruxolitinib treatment, doctors will continue to monitor patients for side effects and disease status for an additional year. Throughout the study, patients will undergo scans such as PET-CT or contrast-enhanced CT or MRI to measure disease response. Researchers will track outcomes like the rate of complete remission and overall response to treatment over 24 months. Safety checks, blood tests, and assessments of organ function will be performed regularly. Patients will be closely followed for side effects during and after treatment to ensure ongoing safety and well-being.

Amping up With PemJAK